Turning to single marker studies, our major low mortality group defined by p53 ≤ 75th percentile and TGF β receptor II ≤ 66th percentile is consistent with literature results for p53, as increased p53 expression has been implicated in poor breast cancer prognosis [42], but potentially inconsistent with results for TGF β receptor II since loss of TGF β receptor II function has been implicated in breast cancer metastasis [43]. This evidence concerns the gene TP53 and breast cancer.